The U.S. Food and Drug Administration (FDA) has given Celyad Oncology permission to begin a Phase 1 clinical trial of CYAD-211, an investigational treatment for relapsed or refractory multiple myeloma. The trial is expected to commence by year’s end. “The FDA’s permission to begin the Phase 1 clinical trial of our lead shRNA-based allogeneic candidate CYAD-211 is a watershed moment for our organization,” Filippo Petti, CEO of Celyad Oncology, said in a press release. “Today’s…
You must be logged in to read/download the full post.
The post Celyad to Begin Phase 1 Trial of Donor-derived CAR T-cell Therapy for Multiple Myeloma appeared first on BioNewsFeeds.